Dianabol and Exemestane Interaction: Avoid | Peptide Database

Join others researching RAD-140 — share findings, ask questions, and learn from real experiences RAD-140 (Testolone) is a nonsteroidal investigational selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. for the potential treatment of muscle wasting conditions and hormone receptor-positive breast cancer. It was designed to provide the anabolic benefits of testosterone, specifically increased lean muscle mass and bone density, while minimizing androgenic side effects in tissues such as the prostate and skin. RAD-140 has demonstrated a high degree of tissue selectivity in preclinical models, with an anabolic-to-androgenic ratio substantially greater than that of testosterone. It entered Phase 1 clinical trials for metastatic breast cancer (ER+/HER2-) and has shown preliminary safety and tolerability in that context. However, RAD-140 is not approved for any medical use by any regulatory agency. It remains a research compound, and its widespread use in performance and physique enhancement contexts is based almost entirely on preclinical data and anecdotal reports rather than completed clinical trials for those indications. RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands. In preclinical studies, RAD-140 demonstrated potent anabolic effects on levator ani muscle mass comparable to testosterone, while showing significantly less stimulation of prostate weight. RAD-140 also crosses the blood-brain barrier and has demonstrated neuroprotective properties in in vitro models, reducing cell death caused by apoptotic insults in hippocampal neurons. At the molecular level, it activates AR-dependent gene transcription pathways involved in protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Importantly, RAD-140 does not undergo aromatization to estrogen and is not a substrate for 5-alpha reductase, meaning it does not produce estrogenic or DHT-mediated side effects. However, like all exogenous AR agonists, it suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis.

Join others researching Anastrozole — share findings, ask questions, and learn from real experiences Anastrozole is a potent, selective, nonsteroidal aromatase inhibitor that blocks the enzyme aromatase (CYP19A1), preventing the conversion of androgens (testosterone and androstenedione) into estrogens (estradiol and estrone). It is FDA-approved under the brand name Arimidex for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In the bodybuilding and hormone optimization community, anastrozole is widely used as an ancillary compound during testosterone or anabolic steroid cycles to manage estrogen-related side effects such as gynecomastia, water retention, and elevated blood pressure. Unlike SERMs, which block estrogen at the receptor, anastrozole reduces circulating estrogen levels directly by inhibiting its synthesis. This distinction is clinically important: while effective at preventing estrogenic side effects, anastrozole carries the risk of suppressing estrogen too aggressively, which can impair joint health, bone density, cardiovascular markers, and mood. A common starting-point rule of thumb: weekly testosterone dose (mg) divided by 500 equals mg of anastrozole per week. For example, 500 mg of testosterone per week would correspond to roughly 1 mg of anastrozole per week, split across injection days. This is only a rough guideline -- individual aromatization rates vary widely, and dosing should always be refined based on bloodwork. Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain. By blocking this conversion, anastrozole reduces circulating estradiol concentrations by approximately 70-80% at the standard 1mg daily dose. In men using exogenous testosterone, aromatase activity is upregulated due to elevated substrate availability, leading to supraphysiological estradiol. Anastrozole counteracts this by limiting estrogen synthesis at the enzymatic level. The inhibition is reversible, meaning estrogen production resumes once the drug is cleared, unlike exemestane which irreversibly inactivates aromatase. Because estrogen plays essential physiological roles in men -- including bone metabolism, lipid homeostasis, neurocognition, and joint lubrication -- the goal of anastrozole use is modulation rather than elimination.